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Androgen receptor (AR) is a major therapeutic target that plays pivotal roles in prostate cancer
(PCa) and androgen insensitivity syndromes.Wepreviously proposed that compounds recruited to
ligand-binding domain (LBD) surfaces could regulate AR activity in hormone-refractory PCa and
discovered several surfacemodulators of AR function. Surprisingly, themost effective compounds
bound preferentially to a surface of unknown function [binding function 3 (BF-3)] instead of the
coactivator-binding site [activation function 2 (AF-2)]. Different BF-3 mutations have been iden-
tified in PCa or androgen insensitivity syndrome patients, and they can strongly affect AR activity.
Further, comparison of AR x-ray structures with and without bound ligands at BF-3 and AF-2
showed structural coupling between both pockets. Here, we combine experimental evidence
and molecular dynamic simulations to investigate whether BF-3 mutations affect AR LBD
function and dynamics possibly via allosteric conversation between surface sites. Our data
indicate that AF-2 conformation is indeed closely coupled to BF-3 and provide mechanistic
proof of their structural interconnection. BF-3 mutations may function as allosteric elicitors,
probably shifting the AR LBD conformational ensemble toward conformations that alter AF-2
propensity to reorganize into subpockets that accommodate N-terminal domain and coacti-
vator peptides. The induced conformation may result in either increased or decreased AR
activity. Activating BF-3 mutations also favor the formation of another pocket (BF-4) in the
vicinity of AF-2 and BF-3, which we also previously identified as a hot spot for a small com-
pound. We discuss the possibility that BF-3 may be a protein-docking site that binds to the
N-terminal domain and corepressors. AR surface sites are attractive pharmacological targets to
develop allosteric modulators that might be alternative lead compounds for drug design.
(Molecular Endocrinology 26: 1078–1090, 2012)
NURSA Molecule Pages†: Nuclear Receptors: AR; Ligands: Dihydrotestosterone.
Androgen receptor (AR, NR3C4) is a ligand-activatedtranscription factor (1) that belongs to the nuclear
receptor (NR) superfamily (2). AR plays specific roles in
male development, prostate cancer (PCa), androgen in-
sensitivity syndromes (AIS), and the rare neurodegenera-
tive spinal and bulbar muscular atrophy (3–13). Like
other NR, AR displays a modular architecture, composed
of anN-terminal domain (NTD), a DNA-binding domain
(DBD), a hinge region, and a C-terminal ligand-binding
domain (LBD) (14). AR LBD adopts the canonical NR
LBD fold (15): a three-layered -helical sandwich with
the ligand buried inside the hydrophobic ligand-binding
ISSN Print 0888-8809 ISSN Online 1944-9917
Printed in U.S.A.
Copyright © 2012 by The Endocrine Society
doi: 10.1210/me.2011-1281 Received October 12, 2011. Accepted April 23, 2012.
First Published Online May 31, 2012
* S.G. and L.R.C. contributed equally to this work.
** E.E-P and J.F-R. are co-corresponding authors.
§ Deceased, October 5, 2011.
† Annotations providedbyNuclear Receptor SignalingAtlas (NURSA) Bioinformatics Resource.
Molecule Pages can be accessed on the NURSA website at www.nursa.org.
O R I G I N A L R E S E A R C H
1078 mend.endojournals.org Mol Endocrinol, July 2012, 26(7):1078–1090
pocket (LBP) [Fig. 1, supporting information (SI); and
Table 1]. The LBD harbors a major coactivator binding
surface [activation function-2 (AF-2)], which acts as a
docking site for short hydrophobic peptide motifs (NR
boxes) featured in AR coactivators and in the AR NTD
and mediates AR functional amino/carboxy (N/C)-termi-
nal interaction (16–20).
Androgen binding is known to trigger widespread
structural and dynamic alterations within the AR LBD,
although detailed structural data are missing. By analogy
with other NR LBDs, unliganded (apo-) AR LBD may fea-
ture a dislodged helix 12 (H12) adopting an unstructured
molten globule organization. Upon admission of the hor-
mone into the core of the LBD, the overall stability of the
domain is increased, achieving a more defined structure
(21). The best-described allosteric rearrangement in NRs
upon ligand binding takes place with the conformational
change of H12 that completes AF-2 (22).
AR LBD is subject to mutations in advanced PCa and
AIS (Androgen Receptor Gene Mutations Database:
http://androgendb.mcgill.ca). PCa mutations often result
in increased transactivation or expanded ligand binding
preference (5, 7, 8, 10, 23, 24). Conversely, AISmutations
usually reduce AR activity and cause varying degrees of
fertility problems and undervirilization (4, 6, 9, 13, 25).
Whereas AR mutations that arise in both diseases com-
monly affect known functional regions of the protein,
including the ligand-binding pocket and AF-2 surface,
many others affect regions of the AR surface with no
assigned function, implying that they disrupt as yet unde-
fined aspects of AR activity.
AR is the pharmacological target for antiandrogens
used in PCa treatment. Current PCa clinical treatments
involve combinations of androgen-deprivation therapy
and antiandrogens (e.g. bicalutamide) that inhibit AR ac-
tion by competing for androgen binding and displacing
H12 to prevent formation of a productive AF-2 pocket.
Unfortunately, prolonged antiandrogen treatment results
in emergence of hormone-refractory PCa with poor prog-
nosis; incompletely defined mechanisms result in reacti-
vation of AR in the absence of androgens and presence of
antiandrogens (12, 26–29).
We have proposed that the AR surface may harbor
attractive sites for intervention with small molecules (30–
33). AR AF-2 undergoes subtle induced fit rearrange-
ments upon coactivator binding and several residue side
chains (e.g., K720, M734, and M894) move to create
hydrophobic subpockets that bind apolar side chains of
coactivator NR boxes and can deepen further to accom-
modate bulky hydrophobic side chains of W/FxxLF mo-
tifs that characterize AR LBD binding peptides within the
NTD- and AR-specific coactivators (19, 20). These sur-
face cavities are attractive targets for small molecules and,
because AR is reactivated in recurrent PCa, such small
molecules could inhibit growth of both early-stage PCa
and late-stage hormone-refractory forms of the disease
(30–33). In a previous study, we screened chemical librar-
ies for small molecules that inhibit coactivator binding to
AF-2 (30). Surprisingly, several compounds, including
Triac and members of the fenamic acid series of antiin-
Abbreviations: AF-2, Activation function 2; AIS, androgen insensitivity syndromes; AR,
androgen receptor; BF-3 and -4, binding functions 3 and 4; DBD, DNA-binding domain;
DHT, dihydrotestosterone; FxxLF, phenylalanine-rich motif; GRIP1, GR-interacting pro-
tein1; H12, helix 12; LBD, ligand-binding domain; LBP, ligand-binding pocket; LxxLL,
Leucine-rich motif; MD, molecular dynamics; N-CoR, nuclear receptor corepressor; NH2/
COOH interaction, amino-terminal/carboxy-terminal interaction; NTD, N-terminal do-
main; NR, nuclear receptor; PCa, prostate cancer; SMRT, silencing mediator of retinoid
and thyroid receptors; SI, supporting information; WT, wild-type.
TABLE 1. Summary of the experimental results obtained in vitro using AF-2 transcriptional activation and
mammalian two-hybrid assays with AR LBD WT and mutant variants, and computational parameters from their
corresponding MD simulations.
AR LBD Site
Luciferase
Activity
Fold Increase
Activity with
GRIP1
Fold Increase
NTD
Interaction
Fold Increase
NCoR
Interaction
Fold Increase
SMRT
Interaction
rel
mean all
b-factor
rel
mean BF-3
b-factor
rel
mean AF-2
b-factor
BF-3-AF-2
corr (r2)
BF-3-LBP
corr (r2)
avgeASA
DHT
WT WT WT WT WT WT 1.00 1.00 1.00 0.34 0.13 0.33
Super-
Activating
N833R BF-3 VERY HIGH LOWER VERY LOW WT LOWEST 0.90 1.36 1.07 0.12 0.05 1.90
R840A BF-3 VERY HIGH WT VERY LOW LOWEST LOWEST 0.87 0.94 1.26 0.50 0.17 1.22
I672R H1-BF-3 VERY HIGH WT VERY LOW LOWER LOWER 1.14 1.53 0.92 0.87 0.03 0.19
PCa
V757A H5 WT HIGHER HIGHER-MILD LOWER LOWER 1.38 1.64 1.14 0.89 0.10 0.14
R726L BF-3 WT HIGHER HIGHER-MILD WT WT 1.13 1.34 1.14 0.72 0.36 2.48
AF-2
AIS
N727K (MAIS) BF-3 HIGHER-MILD HIGHER-MILD LOWER-MILD LOWER WT 0.83 1.14 1.33 0.76 0.16 3.73
AF-2
F826L (PAIS) BF-3 HIGHER-MILD HIGHER-MILD LOWER-MILD LOWER LOWER 0.83 1.04 0.91 0.61 0.01 1.70
Inhibiting
F826R BF-3 LOWER HIGHEST HIGHEST WT LOWER 0.92 0.81 1.12 0.49 0.16 0.33
R840E H1-BF-3 DEAD WT LOWEST LOWER LOWER 0.86 0.87 1.03 0.50 0.01 0.25
Rel, Relative.
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flammatories, inhibited AR/LxxLL peptide interactions
but preferentially were localized by x-ray crystallography
to a distinct surface, binding function 3 (BF-3) (30); BF-3
which is topologically adjacent to, but distinct from,
AF-2, displays characteristics of a protein-binding site,
and is target for PCa and AIS mutations (30–32). Site-
directedmutagenesis of BF-3-lining residues confirmed its
modulating role in AR activity (30). Furthermore, com-
parisons of AR LBD crystal structures with and without
Triac at BF-3 suggested that compound binding triggers
allosteric alterations that propagate to AF-2 and inhibit
coregulator binding (30). Thus, x-ray structures suggest
that BF-3 and AF-2 pockets are structurally coupled and
that allosteric communication between them exists, but
the succession of conformational changes and function of
these effects are not clear.
Here, we employed a combination of in vitro transac-
tivation assays, mammalian two-hybrid assays with AR
LBD, and computational molecular dynamics (MD) sim-
ulations to understand how mutations in residues in or
near BF-3 may influence AR function and dynamics and
how allosteric communication between BF-3 by AF-2
may take place. Our data show that mutations in BF-3 act
as allosteric elicitors of conformational changes that are
transmitted towards AF-2, and that this allosteric com-
munication affects AR LBD function as experimentally
shown in vitro. Furthermore, a series of residues from
BF-3, the boundary of BF-3/AF-2, and AF-2 are structur-
ally interconnected and allosterically coupled. Moreover,
our data indicate that several residues belonging to BF-3
and AF-2 surface pockets are key players of an allosteric
network that may influence multiple aspects of AR LBD
function.
Materials and Methods
Cell culture and transfection assays with AR LBD
Transcriptional activities of wild-type (WT) and mutant hu-
man AR LBD GAL4-DBD constructs (GAL4-AR LBD) were
determined in transient cotransfection assays using human cer-
vix adenocarcinoma epithelial HeLa cells. Vectors and assay
procedures were previously described (20, 30). The GK1-Lu-
ciferase (LUC) reporter plasmid used contained five GAL4 re-
sponse elements upstream of a minimal promoter. GAL4-AR
LBD WT and constructs of mutants I672R, R726L, F826R,
N833R, and R840E have been previously described (30). Mu-
tants N727K, V757A, F826L, and R840A were made by using
the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA). HeLa cells were maintained in Dulbecco’s modified
Eagle, 4.5 g/liter D-glucose medium (GIBCO) containing 10%
fetal bovine serum, 0.58 g/liter L-glutamine, 0.11 g/liter sodium
pyruvate, 100 u/ml penicillin, and 100 mg/ml streptomycin.
Cells were collected 24 h before transfection in fresh medium
containing 10% charcoal-stripped fetal bovine serum and
seeded in 24-well culture plates (Corning, Inc., Corning, NY) at
a density of 1.5 105 cells per well. They were transfected using
FuGENE HD reagent (Promega Corp., Madison, WI) as de-
scribed by the manufacturer. The DNA mixture was composed
of 300 ng/well of GK1-LUC; 2.5 ng/well of Renilla-LUC; 100
ng/well of WT or mutant GAL4-AR LBD or empty control
vector; and 100 ng/well of pSG5-GR-interacting protein
(GRIP)1, VP16-AR NTD (1-504), and VP16-NCoR (1925–
2440) or VP16-SMRT (2025–2525) plasmids. The cells were
incubated 5 h after transfection with vehicle (1%, vol/vol, di-
methylsulfoxide) or hormone [dihydrotestosterone (DHT), dis-
solved in dimethylsulfoxide], which was purchased from Sigma-
Aldrich (St. Louis, MO). Finally, cells were washed twice with
PBS and lysed in 100 l of passive lysis buffer (Promega). LUC
and Renilla-LUC activities were measured on 25 l of the ex-
tracts in a GloMax 96 Microplate Luminometer (Promega) us-
ing the Dual-Luciferase Reporter Assay System (Promega), ac-
cording to the manufacturer’s instructions.
Western blot analysis
For AR Western blot analysis, HeLa cells were transfected
with 1 g of AR LBD expression constructs as described above.
Cells were washed with cold PBS 24 h after hormone treatment,
lysed with cold RIPA buffer (150 mM NaCl, 1% Triton X-100,
0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate and
50 mM Tris, pH 7.5) supplemented with complete protease in-
hibitors (Roche Diagnostics, Indianapolis, IN) and centrifuged
for 10 min at 14,000 rpm. Lysates were boiled and loaded onto
a NuPAGE 4–12% Bis-Tris gel (Invitrogen, Carlsbad, CA), af-
ter which proteins were transferred to a polyvinylidene difluo-
ride membrane. Western immunoblotting was performed using
a polyclonal antibody against the C-terminus of AR (C-19,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), followed by
incubationwith a horseradish peroxidase-conjugatedmouse an-
tirabbit antibody (Abcam, Cambridge, MA). AR LBDs were
visualized by a reaction with Luminata Forte Western HRP
substrate (Millipore).
Molecular dynamic simulations
Preparation of AR LBD input structures
We used the x-ray structure of AR LBD in complex with the
hormone dihydrotestosterone (DHT) (PDB code 1T7T; 1.7 Å
resolution) (19) as starting template to model all the mutants
described herein, using the AMBERmodule LEAP. The PDB file
was converted into an AMBER structure file using LEAP. The
preparation of the files for the hormone DHTwas done with the
AMBER modules ANTECHAMBER and LEAP.
As a first preparation step, the crystallographic water mole-
cules were removed from the structure. Then a quick minimiza-
tion step was performed to optimize the structure within the
force field in vacuum. Later on, each AR LBD structure to study
was placed in a periodic truncated octahedron box of TIP3P
water molecules (the minimum distance between protein and
walls of the boxwas set at 12 Å). Na andCl counterions were
then added to the solvent bulk of protein/water with LEAP to
neutralize the system and achieve 150 mM NaCl concentration.
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System setup and simulation protocol
We performed the MD simulations using the force field
AMBER parm99 of the AMBER10 package (34, 35). Our equil-
ibration protocol for each MD simulation started by 1 psec
minimization with a 50 kcal/(mol  Å2) harmonic potential to
restrain the protein atoms to minimize the solvent molecules.
Then, we applied 40 psec ofMD simulation at constant pressure
(1 atm) with a 12 Å nonbonding cut-off distance during which
the temperature was raised from 50 to 300K using Langevin
dynamics, applying restraints of 25 kcal/(mol  Å2) to all the
protein atoms. After this, we ran 40 psec MD simulation with
restraints of 10 kcal/(mol  Å2), and another 40 psec MD simu-
lation with restraints of 5 kcal/(mol  Å2) on all the protein at-
oms. Then, we applied 20 psec MD simulation with 5 kcal/
(mol  Å2) restraints only to the protein backbone atoms, and
another 20 psecMD simulation with 1 kcal/(mol  Å2) restraints
on the protein backbone atoms as well. Finally, we ran 60 psec
MD simulations in which all the atoms of the system were able
to move freely. After the above-mentioned system equilibration
step, 40 nsec of MD simulation were run for each mutant/com-
plex at constant pressure (1 atm) and a temperature of 300 K.
The particle mesh Ewald method was used, with a collision
frequency of 0.2 psec1 excluding bonds involving hydrogen
atoms.
B-Factors derived from MD simulation
We calculated the temperature factors (B-factors) from the
MD simulation, using the ptraj AMBER tool (35). B-Factors
were computed as atomic positional fluctuations multiplied by
8/32 and then mass weighted and averaged for each residue.
For the sake of comparison, the original B-factors derived from
x-ray diffraction data in the AR LBD PDB 1T7T were also mass
weighted and averaged by residue.
Analysis of cross-correlation matrices
Correlation matrices, representing all the residue-residue
pair-wise root mean square deviation correlations along the
complete MD trajectory, were computed using the ptraj AM-
BER tool (35). The standard convention was used with a posi-
tive value between 0 and 1 reflecting correlated motion and a
negative coefficient between 0 and 1 reflecting anticorrelated
motion. Atoms with correlated motions move in phase whereas
atoms with perfect anticorrelated motion move in antiphase.
Accessible surface area calculations
The hormone DHT accessible surface area (ASA) along the
simulations was computed with the ICM-Browser program
(www.molsoft.com), based on the center of a spherical probe of
1.4 Å radius rolling over the structure of AR bound to the
hormone (36). This parameter gives a measure of the solvent
accessibility of DHT, which is buried within the LBP.
Analysis of surface cavities along MD simulations
To identify the evolution of surface cavities or ligand pockets
during theMD simulations, we used the fpocket program and its
moduleMDpocket developed to track the persistence of pockets
within MD trajectories (37, 38). MDpocket ran fpocket itera-
tively on 100 trajectory snapshots (extracted every 400 psec) to
compute -spheres (defined as those in contact with four atoms
without containing any internal atom inside). Then the density
of the conserved positions of the -spheres during the trajectory
was calculated.High-density regions corresponded to stable and
well-defined cavities whereas lower densities indicated transient
pockets. To visualize all volumes detected by MDpocket for
each trajectory, we used an isovalue of 2.19, which selects the
top 1% of the detected volume for the WT density data.
Contacting pairs and distance calculations
We calculated all contact pairs (residue-residue minimal in-
teratomic distance 4 Å) formed by residues in the peptide-
binding region (i.e. those at a distance 4 Å from the ARA70
peptide in the structure 1T5Z after superimposing AR coordi-
nates) (20), in the snapshots generated every 400 psec from the
MD trajectories. We compared the frequency of such contact
pairs in the mutants with respect to the WT.
Results
BF-3 mutations alter AR AF-2 activity
To address functional effects of different BF-3 muta-
tions, we tested in vitro the transactivation activity of
agonist-bound WT AR LBD (WT AR LBD) and nine AR
LBD mutants (Fig. 1) and performed in parallel an ex-
haustive comparison of dynamics of WT AR and mutant
ARs using MD simulation (see Figs. 2–5 and SI). The
chosen mutated residues are located either lining the BF-3
pocket (I672, F826, N833, R840) or at the boundary
between AF-2 and BF-3, hence part of both pockets
(R726, N727) (Fig. 1, A and B). Additionally, we chose
for control purposes a mutation (V757A) located at the
end of H5, hence distant from both studied pockets (Fig.
1A). The selected dataset of mutations studied herein in-
cludes: I672R (http://androgendb.mcgill.ca), V757A
(39–40), and R726L (41–46), associated with PCa;
F826L (47) and N727K (48), found in AIS patients, as
well as mutations that have not been associated with pa-
thology (F826R, R840A, R840E, and N833R) (Fig. 1, A
and B, and Table 1). We have not studied mutations
F826L, N727K, and R840A before (Fig. 1 and Table 1).
WT and all mutant AR LBDs investigated exhibit com-
parable levels of expressed protein as assessed byWestern
blot (Fig. 1C).
We observe that mutants I672R and N833R behave as
super-AR variants, as earlier reported (30), as well as the
new mutant R840A. Mutants N727K and F826L also
moderately enhance AR AF-2 activity although without
exhibiting super-AR behavior. Also along previous obser-
vations, F826R and R726L marginally reduce, and
R840E totally abolishes AR LBD activity in vitro (Fig. 1D
and Table 1).
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BF-3 mutations affect AR LBD activation by GRIP1
We additionally investigated the functionality of the
studied AR LBDs by measuring AR AF-2 transactivation
activity in vitro in the presence of coactivator and by
addressing AR LBD interaction either with its N-terminal
domain or corepressors using a mammalian two-hybrid
experiment.
We first determined effects of the coactivator GRIP1
on WT and mutant AR activity (Fig. 1E). GRIP1 is the
mouse orthologue of the human protein transcription
intermediary factor 2, which is known to interact with
the AR AF-2 pocket in a hormone-dependent manner
(49). GRIP1 enhances activity of all the mutants, but
there are variations in the extent of GRIP1 potentiation
(Fig. 1E and Table 1). GRIP1 enhances activity of su-
per-mutants I672R and R840A similarly to WT, but
fold increase in activity of supermutant N833R by
GRIP1 is lower. GRIP1 also enhances activity of PCa
mutants V757A and R726L, AIS-associated mutations
F826L and N727K, although to a lesser degree and
FIG. 1. Mutations in AR LBD, AF-2 transcriptional activation, and mammalian two-hybrid assays. A, Simplified model representation of AR LBD
structure. Helices H1, H3, H4–5, H9, and H12 are depicted as gray cylinders. The AF-2 coactivator binding pocket is lined by H3, H5, and H12,
whereas the BF-3 pocket is formed by H1, H9, and the loop linking H3 with H4–5 (L3/4), which is shown as a thin gray wire. BF-3 residues studied
herein are shown as green sticks. Key AF-2 residues implicated in engaging in important contacts with coactivator peptides as shown in previous
crystal structures are highlighted in raspberry, and the charge clamp residues K720 and E897 are shown as rasperry sticks. The residues R726 and
N727 belonging to the boundary between AF-2 and BF-3 pockets are shown as dark blue and green sticks, respectively. The residue V757 the
mutation of which, V757A, has been associated with PCa is depicted as a blue stick located at the end of H5 and is surface exposed. B, Solid-
surface representation of AR LBD in gray showing the residues lining BF-3 in green, the residues lining AF-2 in raspberry and residue R726 in blue.
C, Western blot showing the protein expression level of all AR LBDs. D and E, AR AF-2 activity in the absence (D) or presence (E) of GRIP1
coactivator. WT AR LBD AF-2 activity is 1%. F–H, Mammalian two-hybrid assays with (F) AR NTD domain, and corepressors (G) N-CoR or (H) SMRT.
HeLa cells were transfected with 100 ng DNA and treated with (D–F) 100 nM or 10 nM (G–H) DHT. Results are the mean of at least five
independent experiments performed in triplicate.
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rescues activity of the medium-inhibiting mutant
F826R, resulting in the highest fold increase among all
the studied AR LBD mutants. Even the very weak ac-
tivity of the R840E mutant is enhanced by GRIP1.
Thus, some BF-3 mutations (notably N833R and
F826R) alter the extent of GRIP1 coactivation, but
none abolish GRIP1 interaction.
BF-3 mutations affect the N/C
interdomain interaction
To assess whether mutations at the BF-3 pocket affect
AR LBD/NTD (N/C) interaction, a mammalian two-hy-
brid was performed (Fig. 1F and Table 1). Again, some of
the BF-3 mutants altered AR N/C interaction, but the
pattern of effects was different from that with GRIP1. All
three supermutant AR LBDs, I672R, N833R, and
R840A, show a decreased interaction with the NTD as
compared with WT. Mutants R726L and V757A, asso-
ciated with PCa, display a WT or moderately higher in-
crease in their interaction with the NTD. Medium-inhib-
iting mutant F826R, which exhibited the highest increase
in activity in the presence of coactivator, also exhibits
the largest fold induction with the NTD. Mutants
N727K and F826L, associated with AIS, show mild
impairment in NTD interaction, superactivating mu-
tant N833R exhibits the lowest capacity for N/C inter-
action, and activity of the severely impaired mutant
R840E is not enhanced by NTD overexpression, unlike
the case with GRIP1.
BF-3 mutations alter AR interaction with N-CoR
and SMRT
Because DHT-liganded AR also interacts weakly with
NR corepressors (50), we used a mammalian two-hybrid
assay to assess how BF-3 mutants affect this interaction.
The chosen corepressors were the silencing mediator of
retinoid and thyroid receptors (SMRT) and the nuclear
receptor corepressor (N-CoR) (Fig. 1, G and H).
As seen with GRIP1 and the AR NTD, BF-3 mutants
broadly affect the capacity of AR to bind corepressors
(Fig. 1, G and H, and Table 1). Both supermutants
I672R and R840A exhibit a significant decrease in their
ability to interact with the receptor-interacting do-
mains of corepressors SMRT and N-CoR, being R840
the one that disrupts such interactions the most among
all the AR LBD herein studied. V757A, F826L, and the
severe mutant R840E also reduce corepressor interac-
tion. Supermutant N833R and mutant F826R show
impaired interaction with SMRT, but maintain a WT-
like interaction with N-CoR, whereas N727K de-
creases interaction with N-CoR but leaves interaction
with SMRT unaffected. Finally, R726L has little effect
on corepressor interaction in these assays.
AR LBD MD simulations
To understand the structural and dy-
namic effects of the above-described mu-
tations, we first analyzed WT AR LBD by
running MD simulation for 40 nsec in ex-
plicit solvent, after an initial step to allow
equilibration of AR LBD. The WT AR
LBD structure appeared stable along the
dynamics, and there was no evidence of
large-scale reorganization or denaturation
processes (Fig. 2, A and B).
The overall apparent mobility of WT AR
LBD amino acids along the MD trajectory
resembled that of the AR LBD x-ray struc-
ture PDB 1T7T (19). We estimated residue
B-factor values by computing fluctuations
of each residue along the MD simulation.
Figure 2C shows these values against B-fac-
tor values derived from electron density un-
certainties in the AR LBD structure (19). In
general, B-factors derived fromMD simula-
tion were similar to the crystallographic
ones, implying that our simulation produces
a reasonably accurate representation of the
FIG. 2. Simulation of AR LBD WT and mutants. A, Evolution of root mean square
deviation (RMSD) with respect to the initial structure along the MD trajectory. B,
Evolution of global energy along MD trajectory. C, Comparison between experimental
(in red) and AMBER-based simulated B factors (in green). For consistency, experimental
B factors from PDB 1T7T were transformed to be comparable to simulated values (see
Materials and Methods for details). AMBER B-factors per residue were computed from
an ensemble of 200 frames along the MD trajectory selected every 200 psec. D,
Simulated B-factors mapping on AR. The AR receptor B-factors are shown as worms
with variable thickness and color according to their corresponding value (B-factors  46
in blue; 46  B-factors  77 in white; B-factors  119 in red). ns, Nanoseconds.
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molecular motions that are detected in the crystal al-
though the most N-terminal helix of AR LBD (H1) and
amino acids 687–695 (H1-H3 loop) appear more flexible
in the simulation whereas two highly flexible regions
[amino acids 844–850 (H9-H10) and 880–886 (H11
and H11/12 loop)] appear more rigid than equivalent
regions in the x-ray structure.
Interestingly, the B-factor measurements flag the H3-
H4/5 loop and the S3-H9 loop as relatively flexible com-
pared with other regions of the AR LBD; this was seen
both inMD simulations and in B-factors derived from the
x-ray structure (Fig. 2C and Supplemental Fig.1 for mu-
tant B-factors fluctuations). Both regions are located in
the boundary of AF-2 and BF-3 pockets, suggesting a
possible dynamic link between these binding surfaces
(Fig. 2D).
Next, we studied the effects of mutations on AR LBD
dynamics, by obtaining 40 nsec MD trajectories for each
of the mutants (Supplemental Fig. S2). Interestingly, con-
sideration of mobility of the entire LBD reveals that mu-
tations I672R, F826L, and N727K, which enhance AR
LBD activity, exhibit larger average B-factors (Table 1)
indicative of higher mobility. This is not true for super-
mutants N833R and R840A. On the contrary, inhibitory
AR mutations generally display smaller average B-fac-
tors, indicative of reducedmobility (Table 1). Correlation
of B-factors with activity is even more striking when mo-
bility of only the BF-3 residues is considered (again, ex-
cluding N833R and R840A). There is no similar correla-
tion between mobility of the AF-2 residues and activity
(Table 1).
AR mutations reveal allosteric coupling between
BF-3 and AF-2
To analyze how specific ARmutations affect dynamics
of BF-3 and other regions of the LBD and pinpoint pos-
sible allosteric effects, we computed the motion correla-
tion of all AR residues against each other along the MD
trajectories, shown as correlation matrices (see Supple-
mental Fig. 3 and Materials and Methods). The cross-
correlation plots for WT activating (I672R, F826L) and
inhibiting (R840E) mutations are shown in Supplemental
Fig. 3. The values for WT AR LBD (Supplemental Fig. 3)
show regions that are correlated (in red) or anticorrelated
(in blue) along the MD trajectory. There is little obvious
coupling between different regions of the WT AR LBD.
Interestingly, the correlation matrix for AR I672R shows
significant differences: there is stronger correlation be-
tween motion of residues 672–673 (H1, the mutation
site), residues 710–740 (H3 and loop 3/4, mostly AF-2
and the boundary region of AF-2/BF-3) and residues 820–
840 (the BF-3 lining loop S3/H9 and H9). In the case of
F826L, we observe, in general, less motion correlation
between regions than with I672R, but there is significant
correlation between the region of the mutated residue
(H9, close to BF-3) and the adjacent AF-2 pocket and this
is stronger than WT. Increased correlation of mobility of
BF-3 and AF-2 is not seen with the N833R and R840A
mutants. In the case of R840Emutant, there is lessmotion
correlation and no clearly correlated regions that can be
highlighted. Reductions in correlation between mobility
of the BF-3 and AF-2 pockets are also seen with other
BF-3 mutants that reduce AR LBD activity.
Calculation of correlation coefficients (r2) along the
MD trajectories between the residues forming BF-3,
AF-2, and LBP (where DHT is bound) sites underscores
impressions from themobility correlationmatrices (Table
1). Activating mutants (with the exception of N833R and
R840A) have BF-3/AF-2 correlation r2more than 0.7 (sig-
nificantly higher than WT), whereas inhibiting mutants
have r2 around 0.5–0.6, smaller than that of the activat-
ing mutants, but still higher than WT. Thus, there is in-
creased allosteric coupling between BF-3 and AF-2 when
the transcriptional output is enhanced activation.
We do not observe any correlation between AF-2 or
BF-3 and residues that line the LBP for WT AR or any of
the analyzed AR mutants. Curiously, if we exclude the
most activating mutants (N833R, R840A, I672R, and
F826L), there is some correlation between the average
DHT ASA relative to WT and activity (Supplemental Fig.
4). This raises the possibility that enhanced plasticity of
LBP observed during MD simulations may favor AR
activity.
BF-3 mutations change dynamics of AF-2
Because the results obtained from ourMD simulations
suggest close structural communication between BF-3
and AF-2 surface pockets, we analyzed effects of BF-3
mutations on AF-2 conformation in more detail. To do
this, we computed all possible contact pairs of AF-2 res-
idues that exhibited at least a 15% reduction or increase
in their pair-wise interaction frequency relative toWTAR
during simulations (see Materials and Methods for de-
tails). Figure. 3 and Supplemental Figs. 5 and 6 show
evolution of contacts between selected residue pairs along
the simulations.
BF-3 mutations result in significant changes in pair-
wise interactions within AF-2 residues over time. For ac-
tivating mutants I672R and F826L, the proximity be-
tween the AF-2 key residues K720-M734 is greatly
reduced relative toWTAR or R840E (Fig. 3). In contrast,
K720 (one of the charge clampAF-2 residues) formsmore
extensive contacts with H729, N727, L728, and V730.
Among other AF-2 residues, M734 establishes frequent
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contacts with L712, M894, and I898, whereas V730
formsmore frequent contacts with V716 in the context of
both activating mutants. Effects of the AR R840E (inhib-
itor) mutation are opposite to that of the activating mu-
tants. Specifically, pair-wise interactions between K720
and M734 are enhanced, whereas interactions between
R726, K720, Q733, and V730 appear less frequently,
V730 remains further away from K720 and V716, and
contacts between K720 and Q733 are less prevalent
(whereas contacts between K720 and H729, N727, or
L728 are never formed, as in WT).
The net effect of these changes in pair-wise interactions
is that there are alterations in the frequency of formation
of AF-2 subpockets that accommodate bulky side chains
of F1xxLF5 peptides present in AR-specific coactivators
(Supplemental Fig. 7). In the x-rayWTAR structure (PDB
1T7T) (19), K720 and M734 are in contact, closing the
entrance for the second F side chain (at position 5) of the
FxxLF motif (Fig. 4A). During the WT MD simulation,
these residues open frequently to create an organization
that resembles that of AR in complex with the ARA70
FxxLF motif (PDB 1T5Z) (20) (Fig. 4B). In the I672R
mutant simulations, K720 andM734 separate even more
widely and frequently, opening a larger hydrophobic
pocket (Fig. 4E), an effect that can also be seen in the
other activating mutant F826L (data not shown). By con-
trast, in the AR R840E (inhibitor) mutant, the arrange-
ment of K720 and M734 along the simulation resembles
that of the original AR x-ray structure PDB 1T7T (19),
and the deep AF-2 subpocket fails to
open (Fig. 4F), unlike the dynamic
opening and closing of the subpocket
seen in simulations with WT AR (Fig.
4D). Thus, MD simulations seem to
suggest that BF-3 mutations alter the
propensity of AF-2 to form subpockets
that accommodate FxxLF peptides; ac-
tivating mutations enhance subpocket
formation, whereas the inhibitory muta-
tion reduces subpocket formation.
Allosteric paths on AF-2
We examined snapshots of the MD
simulations to search for dynamic
structural rearrangements that could
be responsible for the allosteric trans-
mission of information from BF-3 to
AF-2 (Fig. 5). Analysis of the simula-
tions of activating AR mutants I672R
and F826L revealed a large conforma-
tional change in theH3-H4/5 loop (res-
idues 723–734) toward the end of the
simulation (see a conformational snap-
shot of I672R in Fig. 5B).Movements of this loop relative
to the initial position (Supplemental Fig. 8) were more
extensive than the ones seen in WT AR or any other
mutant simulation [interestingly, the mutants with higher
fold increase in activity in the presence of GRIP1 (V757A,
R726L and, to a lower extent, F826R), have these loops
more extensively moved than WT along the dynamics].
Within the H3–H4/5 loop, there are striking changes in
the spatial location of residues H729 and V730 (Fig. 3). A
possible mechanism for this effect is that the I672R side
chain interacts with E837 (located in H9 and forming a
salt bridge with R840 in WT AR). This effect would alter
H9 position and free the H3–H4/5 loop so that K720
(H3) can interact with H729 (H3-H4/5 loop). H729
moves from being in contact with a lysine residue (K822,
loop S3-H9) to contacting K720 backbone as a result of
the new loop conformation.
Similar analysis for F826L (Fig. 5E) also reveals
opening of the H3–H4/5 loop. Early in the MD simu-
lation, L826-N823 interaction breaks leading to dis-
tortion of the S3-H9 loop and breakage of K822-H729
contact. This effect, which is not seen in WT AR, leaves
H729 free to interact with K720 and results in a H729-
K720 conformation that is exactly the same as the one
seen in the I672R simulation and is not found in any
other mutant. By contrast, the K822-H729 contact is
more stable in the simulations with the R840E inhibi-
tory mutant relative to WT-AR and certainly much
FIG. 3. Evolution of pair-wise minimal contact distance for selected residue pairs in WT AR
(blue), I672R mutant (green), F826L mutant (red), and R840E mutant (magenta) along the MD
trajectory for selected residue pairs. ns, Nanoseconds.
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more stable than in activating mutants (Fig. 3), under-
scoring the potential importance of this interaction in
BF-3/AF-2 communication.
These new conformations of the H3-H4/5 and S3-H9
loops (especially in the activating mutants) open a small
hydrophobic cavity around Y739 (H4) that is adjacent to
AF-2 and close to BF-3. Comparison of the organization
of this cavity reveals that it is closed throughout the sim-
ulations with the inhibitor mutation R840E.
Discussion
We have previously discovered a small molecule-binding
surface on the AR LBD (BF-3), and our mutational anal-
ysis has revealed that it is highly important for AR func-
tion (30). AR mutants that affect BF-3 and have been
documented in PCa and AIS variously influence androgen
binding and dissociation, coregulator recruitment, N/C-
interaction, and transactivation (6, 7, 30, 42, 47, 51–69).
We envision two possible physiological roles for BF-3,
which are not mutually exclusive. First, our combined
functional and computational assays support our pre-
vious hypothesis that BF-3 is an allosteric modulator of
the adjacent AF-2 pocket, affecting its function. Sec-
ond, BF-3 may be a protein-protein interaction site for
coregulator proteins.
Our studies confirm and extend our
previous data, which show that BF-3
mutants alter overall AR activity in
different, and hard to predict, ways.
We show that mutants in BF-3 and res-
idues that lie between BF-3 and AF-2
produce a range of effects from super-
activators (I672R, N833R, R840A),
moderate enhancers (F826L, N727K),
weak inhibitors (F826R, R726L), and
very potent inhibitors (R840E). We
have also shown awide range of effects
upon coregulator binding; BF-3 muta-
tions do not completely inhibit func-
tional interactions with GRIP1 or NTD
but do affect coactivation differentially
by both proteins. This stands in marked
contrast to effects of mutations in the
AF-2 surface that consistently block AR
interactions with GRIP1, the AR NTD,
and other coregulators. Finally, BF-3
mutations moderately inhibit corepres-
sor interactions, but, here again, there
are diverse effects with some mutations
strongly inhibiting N-CoR and SMRT
binding, others exhibiting milder effects
or no effects, and some distinguishing between N-CoR and
SMRT.
Our MD simulations do not systematically explain ef-
fects of all AR BF-3 mutations but do suggest a plausible
general explanation for their diverse effects on AR activ-
ity; BF-3 is coupled to AF-2, and BF-3 mutations alter the
propensity of the AF-2 surface to form deep subpockets
that accommodate bulky side chains of coregulator mo-
tifs. MD simulation on AR LBD shows a dynamic link
between BF-3 and AF-2, and two regions that form the
boundary between AF-2 and BF-3 pockets play a key role
in allosteric communication: the H3-H4/5 loop, where
R726 and N727 are located, and the S3-H9 loop, where
F826 resides. Interestingly, consideration of mobility of
the entire LBD reveals that three mutations that enhance
AR LBD in vitro activity (I672R, F826L, N727K), exhibit
a greater mobility than WT. On the contrary, AR inhib-
itory mutations generally feature smaller mobility with
respect to WT. Analysis of the flexibility per pocket indi-
cates that BF-3 flexibility degree is inversely correlated to
the AR LBD in vitro function, but there is no correlation
with the AF-2 mobility.
BF-3 mutations induce conformational changes in sev-
eral side chains of the adjacent AF-2 pocket. For activat-
ing mutants I672R and F826L, residues K720 and M734
stand out as already observed in the x-ray crystal struc-
FIG. 4. Surface residues of the AF-2 pocket. A, WT AR x-ray structure, PDB 1T7T. B, AR
bound to ARA70 peptide x-ray structure, PDB 1T5Z. C, AR bound to ARA70 peptide, with
peptide removed for the sake of clarity. D, WT AR during MD simulation (snapshot taken at
10.4 nsec, representative of the first third of the trajectory). E, I672R mutant during MD
simulation (snapshot taken at 29.6 nsec, representative of the last half of the trajectory). F,
R840E mutant during MD simulation (snapshot taken at 4 nsec, representative of the first half
of the trajectory).
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tures of coactivator peptides bound to AF-2 (20). Pair-
wise residue contacts with several key AF-2 residues are
manifested, specially implicating L712, H729, N727,
L728, V730, and H12 M894 and I898. Effects of the AR
R840E (inhibitor) mutation on the observed pair-wise
contact formation are opposite to that of the activating
mutants. The net effect of these changes in pair-wise in-
teractions is alterations in the frequency of formation of
AF-2 subpockets that accommodate NR boxes present in
coactivator peptides and the NTD domain. There is thus
a shift in the conformational ensemble of the AF-2
groove. Residues K720 and M734, which are in a closed
conformation in the x-ray WT AR structure without co-
activator peptide (PDB 1T7T) (19), remain more fre-
quently along the MD trajectory in the AF-2
open conformation, similar to the one ob-
served in the crystal structure of AR bound to
the ARA70 FxxLF motif (PDB 1T5Z) (20). In
the I672R and F826L mutant MD simulation,
K720 and M734 separate even more widely,
frequently opening a larger hydrophobic
pocket. However, K720 and M734 are found
in the closed conformation along the MD tra-
jectory in the inhibitory AR mutant R840E.
Thus, MD simulation suggests that BF-3 mu-
tations alter the propensity of AF-2 to reorga-
nize its subpockets to accept the entering co-
activator peptides. Whereas several activating
mutations enhance the formation of subpock-
ets, inhibitory ones reduce them.
Other paths may also be involved in the
allosteric transmission of information from
BF-3 to AF-2, and from/to other areas of the
receptor. Our studies have evidenced possible
roles for identified residues located in the H3-
H4/5 and S3-H9 loops that are responsible for
conformational changes and allosteric cross
talk among AR LBD surfaces. These new con-
formations of the H3-H4/5 and S3-H9 loops
(especially in the activating mutants) open a
small hydrophobic cavity around Y739 (H4)
that is adjacent to AF-2 and close to BF-3.
Comparison of the organizations of this cavity
reveals that it is closed throughout the simula-
tions in the inhibitor mutation R840E. Inter-
estingly, we observed weak binding of an apo-
lar small molecule (salycylaldehyde) at this
cavity adjacent to AF-2 in our initial screening
of surface inhibitor compounds (PDB 2PIR)
(30). Y739 is one of the residues that inter-
acted with this surface binder drug, and, most
importantly, K822 (loop S3-H9) was at a dis-
tance that allowed electrostatic stabilization of the drug
(30).We call this groove “binding function 4” (BF-4).We
did not observe correlation between AF-2 or BF-3 and the
residues that line the LBP for WT AR or any of the AR
analyzed mutants. However, it is interesting to point out
that if the most activating mutants are excluded (N833R,
R840A, I672R, and F826L), there seems to be a correla-
tion between the average ASA of the LBP, where DHT is
cocooned, indicating that an increase in LBP adaptability
during the MD simulation may influence AR activity.
Our data indicate that two superactivating BF-3 mu-
tations may work by a distinct mechanism. Our MD sim-
ulations evidence that N833R and R840A do not exhibit
larger overall flexibility than WT AR, unlike I672R and
FIG. 5. Conformational changes in WT AR and mutants during MD simulation. A,
Detail of the H3–H4/5 loop in WT AR during MD simulation (in gray, snapshot taken
at 10.4 nsec, representative of the first third of the trajectory) with respect to the
x-ray structure in yellow. B, I672R mutant after MD simulation (in gray, snapshot
taken at 29.6 nsec, representative of the last half of the trajectory) compared with
WT AR x-ray structure (in yellow). C, Same loop detail in R840E mutant after MD
simulation (in gray, snapshot taken at 4 nsec, representative of the first half of the
trajectory) compared with WT AR x-ray structure (in yellow). D, Residue pairs in
which contact frequency during MD simulation in I672R mutant significantly change
with respect to the AR WT simulation; residues are represented as spheres, and the
link is colored in red or green depending whether the contact frequency in the
corresponding AR mutant MD simulation is significantly smaller or larger,
respectively, than in WT AR MD simulation. E and F, Similar analysis for F826L
mutant (E), and for R840E mutant (F).
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other activating mutations, suggesting that they enhance
AR activity via a mechanism that differs from allosteric
communication. Because BF-3 exhibits characteristics of
a protein interaction surface, it is attractive to speculate
that both mutations could alter direct contacts with an
unknown protein(s) that could either potentiate or silence
AR function. Several lines of evidence suggest that BF-3
could be involved in protein contact. Equivalent regions
of the thyroid hormone receptor (70) and the nuclear
receptor LRH-1 bind to corepressor and the wnt-signal-
ing dependent coactivator -catenin (71). Furthermore,
functional evidence links this region of AR to contacts
with the chaperone FKBP52 (72). It is even possible that
BF-3 might contact GRIP1 coactivator, the NTD, and
corepressors and that these proteins have an interaction
surface on AR LBD that extends beyond the AF-2 pocket
toward BF-3 as we have previously suggested (30, 33).
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